Hofseth BioCare Performance dei guadagni passati
Il passato criteri di controllo 0/6
Hofseth BioCare's earnings have been declining at an average annual rate of -15.6%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 12.5% per year.
Informazioni chiave
-15.6%
Tasso di crescita degli utili
-6.2%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 11.5% |
| Tasso di crescita dei ricavi | 12.5% |
| Rendimento del capitale proprio | -123.9% |
| Margine netto | -103.8% |
| Prossimo aggiornamento sui guadagni | 25 Aug 2023 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Ripartizione dei ricavi e delle spese
Come Hofseth BioCare guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 23 | 134 | -140 | 76 | 0 |
| 31 Dec 22 | 120 | -137 | 76 | 0 |
| 30 Sep 22 | 113 | -136 | 66 | 0 |
| 30 Jun 22 | 96 | -139 | 64 | 0 |
| 31 Mar 22 | 102 | -135 | 63 | 0 |
| 31 Dec 21 | 88 | -126 | 60 | 0 |
| 30 Sep 21 | 85 | -120 | 44 | 0 |
| 30 Jun 21 | 79 | -115 | 47 | 0 |
| 31 Mar 21 | 68 | -111 | 45 | 0 |
| 31 Dec 20 | 69 | -102 | 43 | 0 |
| 30 Sep 20 | 57 | -104 | 46 | 0 |
| 30 Jun 20 | 79 | -90 | 37 | 0 |
| 31 Mar 20 | 72 | -86 | 36 | 0 |
| 31 Dec 19 | 68 | -89 | 34 | 0 |
| 30 Sep 19 | 71 | -79 | 41 | 0 |
| 30 Jun 19 | 59 | -81 | 42 | 0 |
| 31 Mar 19 | 61 | -83 | 42 | 0 |
| 31 Dec 18 | 61 | -85 | 43 | 0 |
| 30 Sep 18 | 73 | -74 | 36 | 0 |
| 30 Jun 18 | 84 | -66 | 36 | 0 |
| 31 Mar 18 | 75 | -66 | 36 | 0 |
| 31 Dec 17 | 66 | -16 | 34 | 0 |
| 30 Sep 17 | 43 | -28 | 27 | 0 |
| 30 Jun 17 | 19 | -60 | 24 | 0 |
| 31 Mar 17 | 21 | -92 | 21 | 0 |
| 31 Dec 16 | 20 | -147 | 21 | 0 |
| 30 Sep 16 | 21 | -165 | 26 | 0 |
| 30 Jun 16 | 34 | -137 | 28 | 0 |
| 31 Mar 16 | 32 | -109 | 28 | 0 |
| 31 Dec 15 | 32 | -100 | 27 | 0 |
| 30 Sep 15 | 38 | -84 | 22 | 0 |
| 30 Jun 15 | 23 | -82 | 22 | 0 |
| 31 Mar 15 | 24 | -72 | 22 | 0 |
| 31 Dec 14 | 20 | -67 | 22 | 0 |
| 30 Sep 14 | 39 | -40 | 27 | 0 |
| 30 Jun 14 | 62 | -35 | 30 | 0 |
| 31 Mar 14 | 63 | -39 | 30 | 0 |
| 31 Dec 13 | 63 | -52 | 31 | 0 |
| 30 Sep 13 | 41 | -98 | 31 | 0 |
| 30 Jun 13 | 27 | -96 | 26 | 0 |
| 31 Mar 13 | 26 | -89 | 26 | 0 |
| 31 Dec 12 | 26 | -74 | 24 | 0 |
| 30 Sep 12 | 20 | -35 | 17 | 0 |
| 30 Jun 12 | 9 | -32 | 15 | 0 |
Guadagni di qualità: HBCO is currently unprofitable.
Margine di profitto in crescita: HBCO is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: HBCO is unprofitable, and losses have increased over the past 5 years at a rate of 15.6% per year.
Accelerare la crescita: Unable to compare HBCO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: HBCO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Rendimento del capitale proprio
ROE elevato: HBCO has a negative Return on Equity (-123.89%), as it is currently unprofitable.